Highlights
- First Victorian Empax clinic set to commence patient treatments in Q2 CY2026
- 31 therapists and six psychiatrists contracted and trained to ensure operational readiness
- Dual reimbursement pathways via Medibank Private and DVA support early revenue visibility
Emyria Limited (ASX:EMD) is progressing toward the launch of its first Victorian Empax clinic, with patient treatments on schedule for Q2 CY2026. The clinic forms a key part of Emyria’s national rollout strategy, increasing capacity to deliver reimbursable, evidence-based mental health treatments. The company has trained 31 therapists and six psychiatrists, ensuring workforce readiness and scalability. Operational milestones, including agreements with Avive Health and secured medication supply, reduce execution risk. Dual reimbursement pathways from Medibank Private and the Department of Veterans' Affairs further support early patient uptake and revenue visibility.
Operational and Clinical Readiness
Emyria has finalized agreements with Avive Health, allowing minor clinic fit-outs and integration of clinical governance processes. Workforce preparation includes 31 therapists and four trained psychiatrists, with two more scheduled in Q2 CY2026, ensuring sufficient capacity for patient throughput. Medication supply and pharmacy agreements are in place, mitigating execution risks. These steps establish a strong foundation for the clinic’s operational launch and support a smooth ramp-up phase post-opening.
Revenue Pathways and Strategic Expansion
Revenue visibility is strengthened through dual reimbursement channels. Medibank Private funds eligible patients for Treatment-Resistant Depression and PTSD treatments at the Mornington Peninsula facility, while the Department of Veterans’ Affairs provides funding for veterans accessing medication-assisted therapy. These pathways underpin early utilisation rates, reducing reliance on self-funded patients. The Victorian clinic expands Emyria’s treatment footprint, increases capacity, and positions the company to scale the Empax model nationally. Executive Chairman Greg Hutchinson emphasized the clinic’s potential to drive growth and access to evidence-based mental health care.
FAQs
- When will Emyria’s Victorian Empax clinic start treatments?
Patient treatments are on track to commence in Q2 CY2026.
- How many clinicians are ready for the clinic launch?
The clinic has 31 trained therapists and six psychiatrists, with two more psychiatrists scheduled in Q2 CY2026.
- How is revenue supported for the new clinic?
Revenue is backed by dual reimbursement pathways through Medibank Private and the Department of Veterans' Affairs
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
This report (“Report”) has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this Report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).
The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not issue, sell or deal in any financial products. The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.
This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes.
Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Report, or its content, may be reproduced in any form without our prior consent.